Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Procter & Gamble

Home Building Data Disappoints

Johnson & Johnson (NYSE: JNJ) is trading higher Tuesday after the company announced better-than-expected third-quarter earnings results and raised guidance. Johnson & Johnson reported quarterly adjusted earnings of $2.60 per share, which beat the estimate of $2.36 per share.

Why Johnson & Johnson Shares Are Trading Higher Today

Johnson & Johnson (NYSE: JNJ) beat Wall Street estimates for earnings in the fiscal third quarter despite a slight miss on the sales front. Shares of the company were up 1.0% in premarket trading on raised full-year guidance.

Johnson & Johnson CFO defends sales miss in fiscal Q3

Johnson & Johnson and Procter & Gamble fell in premarket trading, but that didn't cool off investor sentiment.

Tuesday Could Be a Winning Market Day Despite Earnings Headwinds From These 2 Stocks

Johnson & Johnson made just $502 million in global sales of its COVID-19 vaccine in the most recent quarter -- falling far short of quarterly revenue from peers Pfizer and Moderna.

Johnson & Johnson made $502M from COVID vaccine in third quarter

Shares of Johnson & Johnson JNJ, -0.73% were up 0.1% in premarket trading on Tuesday after the company said it brought in $502 million in worldwide sales of its COVID-19 vaccine in the third quarter of 2021 as part of its earnings report. That adds up to a total of $766 million in sales of its COVID-19 shot so far this year.

J&J's COVID-19 shot generated $502 million in sales in the third quarter

Johnson & Johnson (NYSE: JNJ) has reported Q3 adjusted earnings of $2.60 per share, up 18% Y/Y over the $2.20 posted a year ago and better than the consensus of $2.36.  Net sales increased 10.6% Y/Y to $23.3 billion, ahead of the consensus of $23.7 billion.

Johnson & Johnson Shares Gain After Q3 Earnings Beat Wall Street; Raises FY21 Guidance

This vaccine could come from its candidate that prevents a little-known respiratory virus.

Johnson & Johnson May Not Have to Wait Long for Its Next Blockbuster Vaccine

Johnson & Johnson shares JNJ, -0.73% rose 1.6% in premarket trading Tuesday, after the consumer goods and pharmaceuticals company posted better-than-expected third-quarter profit and raised its full-year guidance. The New Brunswick, NJ.

J&J beats profit estimates for latest quarter as sales fall short and company raises full-year guidance

Johnson & Johnson said it sold $502 million of its Covid-19 vaccine in the third quarter, in its earnings report Tuesday that beat Wall Street's profit and revenue expectations.

J&J Covid vaccine adds $502 million to third-quarter sales

Johnson & Johnson (JNJ.N) on Tuesday raised its adjusted profit forecast for 2021, even as it stuck to its outlook of $2.5 billion in sales from its COVID-19 vaccine this year.

J&J raises 2021 profit view, keeps vaccine sales outlook unchanged

NEW BRUNSWICK, N.J., Oct. 19, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021.

Johnson & Johnson Reports Q3 2021 Results

At least initially. It could be a different story over the longer term.

Why Johnson & Johnson Will Be a Bigger Winner With Boosters Than Pfizer and Moderna

Moderna

The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.

J&J, Moderna COVID-19 Booster Jabs Near FDA Authorization

The FDA's Vaccines and Related Biological Products Advisory Committee voted 19-0 to authorize a second shot of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine to follow at least two months after the initial dose. Related Link:   Johnson & Johnson COVID-19 Booster Shot Generates 9X Spike-Binding Antibodies, Early Data Shows.

Johnson & Johnson's COVID-19 Booster Dose Wins FDA Adcomm Backing

These are Insider's biggest healthcare stories for October 18.

We're getting closer to a J&J booster shot

Johnson & Johnson stock is scheduled to report its Q3 2021 results on Tuesday, October 19. We expect J&J to report revenues and earnings slightly above the consensus estimates.

Will Johnson & Johnson Stock Rise After Q3 Results?

Apple

This mobile device mogul and healthcare hero can help your portfolio weather the stock market's storms.

2 Top Stocks for a Solid Portfolio Foundation

Coca-Cola

These three Dividend Kings have solid long-term track records of increasing payments.

Forget FedEx: Here Are 3 Better Dividend Stocks

Johnson & Johnson (NYSE: JNJ) shares have weakened from their recent highs above $180, and the current share price stands at $161. Johnson & Johnson is scheduled to announce third-quarter earnings results on Tuesday, October 19th, before the market opens, and according to estimates, the company should post strong earnings results.

Should I buy Johnson & Johnson shares ahead of third-quarter earnings results?

Brookfield Renewable Partners

Innovative Industrial Properties

They're resilient and already offer attractive dividends.

3 Dividend Stocks to Buy If the Stock Market Crashes

Will Johnson & Johnson Win Authorization for Its COVID-19 Booster?

Duke Energy

Alphabet

This stock trio is perfectly positioned to help investors navigate a possible downturn.

The Safest Stocks to Buy if There's a Stock Market Crash

Intel

Netflix

Snap

Tesla

The big banks got us off to a flying start in this Q3 earnings season, but we will get a true sense of how good or otherwise the corporate profitability picture is after seeing the coming week's reporting docket.

Into the Heart of Q3 Earnings Season

Millions of Americans are likely to get Johnson & Johnson boosters now that the FDA's expert panel has unanimously recommended it.

News for Johnson & Johnson Stock (JNJ)